Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

PURPOSE: The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secr...

詳細記述

保存先:
書誌詳細
主要な著者: Von Hoff, Daniel D., Ramanathan, Ramesh K., Borad, Mitesh J., Laheru, Daniel A., Smith, Lon S., Wood, Tina E., Korn, Ronald L., Desai, Neil, Trieu, Vuong, Iglesias, Jose L., Zhang, Hui, Soon-Shiong, Patrick, Shi, Tao, Rajeshkumar, N.V., Maitra, Anirban, Hidalgo, Manuel
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2011
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3565012/
https://ncbi.nlm.nih.gov/pubmed/21969517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.5742
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料